Study the Safety and Effectiveness of Tadalafil in Men With Problems Getting or Maintaining an Erection When Taken Prior to Desiring an Erection

  • Tell a FriendPrint

Study to determine how safe and effective tadalafil is for Japanese men taking it when they need to get and keep an erection...

Brief Summary

Official Title: “A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Tadalafil Administered "On Demand" to Patients With Erectile Dysfunction”

Study to determine how safe and effective tadalafil is for Japanese men taking it when they need to get and keep an erection.

  • Study Type: Interventional
  • Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Intervention(s) in this Clinical Trial

  • Drug: tadalafil
    • 5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
  • Drug: placebo
    • placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
  • Drug: tadalafil
    • 10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
  • Drug: tadalafil
    • 20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks

Arms, Groups and Cohorts in this Clinical Trial

  • Placebo Comparator: 1
    • Placebo tablet
  • Active Comparator: 2
    • 5 mg tadalafil
  • Active Comparator: 3
    • 10 mg tadalafil
  • Active Comparator: 4
    • 20 mg tadalafil

Outcome Measures for this Clinical Trial

Primary Measures

  • Effectiveness measured by IIEF score of questions 1-5 and 15 plus the percentages of positive responses to questions 2 and 3 in SEP diary
    • Time Frame: 12 weeks

Secondary Measures

  • Change from baseline to endpoint of various questions from the IIEF and SEP diary
    • Time Frame: 12 weeks

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • 3 months history of erectile dysfunction (ED)
  • Anticipate a monogamous relationship with a female sexual partner
  • Be able to make minimum required sexual intercourse attempts
  • Abstain from using any other ED treatment

Exclusion Criteria:

  • Other primary sexual disorders
  • History of radical prostatectomy or other pelvic surgery that affected being able to have an erection
  • History of penile implant or clinically significant penile deformity.
  • Nitrate use
  • Certain heart problems

Gender Eligibility for this Clinical Trial: Male

Minimum Age for this Clinical Trial: 20 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Investigator Information

Lead Investigator: Eli Lilly and Company Industry

Overall Clinical Trial Officials and Contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Study Director Eli Lilly and Company  

Additional Information

Information obtained from ClinicalTrials.gov on February 09, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00547495

Study ID Number: 5139

ClinicalTrials.gov Identifier: NCT00547495

Health Authority: Japan: Pharmaceuticals and Medical Devices Agency

Lilly Clinical Trial Registry

  • Tell a FriendPrint

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.

The URL of this page is:
http://clinicaltrialsfeeds.org/clinical-trials/show/NCT00547495